Guardant Health Unveils Promising Results from RADIOHEAD Study, Highlighting Early Detection of Immunotherapy Response in Advanced Cancer Patients
I'm PortAI, I can summarize articles.
Guardant Health, Inc. has released promising results from the RADIOHEAD study, conducted in collaboration with the Parker Institute for Cancer Immunotherapy. The study, published in Cancer Research Communications, shows that Guardant Reveal, a tissue-free monitoring tool, can detect immunotherapy responses in advanced cancer patients up to five months earlier than traditional methods. Involving over 500 patients, the findings highlight the potential of blood-based monitoring to enhance treatment decision-making in cancer care.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments